Dr. Agarwal's Health Care Limited

Dr. Agarwal’s Health Care Limited announced that its Nomination and Remuneration Committee approved the allotment of 18,200 equity shares to eligible employees and its subsidiary following the exercise of options under the Dr. Agarwal’s Health Care Limited – Employees Stock Option Scheme 2022. The allotment, made on October 20, 2026, increased the company's paid-up equity share capital from Rs 31,70,26,183 consisting of 31,70,26,183 equity shares to Rs 31,70,44,383 consisting of 31,70,44,383 equity shares.

Dr. Agarwal’s Health Care Limited announced that the Scheme of Amalgamation between Dr. Agarwal’s Eye Hospital Limited and Dr. Agarwal’s Health Care Limited has become effective from November 1, 2026, with an Appointed Date of April 1, 2026, following the filing of the National Company Law Tribunal order with the Registrar of Companies in Chennai on October 15, 2026. The board also approved the reclassification of Dr. Agarwal’s Eye Hospital Limited’s authorized share capital of 20,00,00,000 Equity Shares of Rs 1 face value and its subsequent combination with Dr. Agarwal’s Health Care Limited’s authorized share capital, increasing the latter’s total authorized capital to Rs 110 crore. Additionally, November 18, 2026, has been fixed as the Record Date for allotment of consideration shares to eligible shareholders of Dr. Agarwal’s Eye Hospital Limited, with a share exchange ratio of 23 shares of Dr. Agarwal’s Health Care Limited for every 2 shares of Dr. Agarwal’s Eye Hospital Limited.

Dr. Agarwal’s Health Care Limited announced that the Scheme of Amalgamation between Dr. Agarwal’s Eye Hospital Limited and Dr. Agarwal’s Health Care Limited has become effective from November 1, 2026, with an Appointed Date of April 1, 2026, following the filing of the National Company Law Tribunal order with the Registrar of Companies in Chennai on October 15, 2026. The board also approved the reclassification of Dr. Agarwal’s Eye Hospital Limited’s authorized share capital of 20,00,00,000 Equity Shares of Rs 1 face value and its subsequent combination with Dr. Agarwal’s Health Care Limited’s authorized share capital, increasing the latter’s total authorized capital to Rs 110 crore. Additionally, November 18, 2026, has been set as the Record Date for allotment of consideration shares to eligible shareholders of Dr. Agarwal’s Eye Hospital Limited, with a share exchange ratio of 23 shares of Dr. Agarwal’s Health Care Limited for every 2 shares of Dr. Agarwal’s Eye Hospital Limited.

Dr. Agarwal’s Health Care Limited submitted a certificate to the BSE Limited and National Stock Exchange of India Limited on October 7, 2026, confirming the details of securities dematerialized and rematerialized for the quarter ended September 30, 2026, as per Regulation 74(5) of the Securities and Exchange Board of India (Depositories and Participants) Regulations, 2018, with KFin Technologies Limited acting as the Registrar and Share Transfer Agent.

Dr. Agarwal’s Health Care Limited announced that the Hon’ble National Company Law Tribunal, Chennai Bench, has sanctioned the Scheme of Amalgamation between Dr. Agarwal’s Eye Hospital Limited and Dr. Agarwal’s Health Care Limited, effective from April 1, 2026, with the Scheme becoming operative from the month following the completion of all conditions outlined in Clause 24.

Dr. Agarwal’s Health Care Limited announced on Tuesday, September 29, 2026, that Orbit Healthcare Services Nigeria Ltd. has become a wholly owned subsidiary of Orbit Mauritius, a direct wholly owned subsidiary of Dr. Agarwal’s Health Care Limited, following an intimation received from Orbit Mauritius.

Dr. Agarwal’s Health Care Limited announced that Sanjay Anand will cease to be an Independent Director of the company upon completion of his five-year term at the close of business hours on September 29, 2026, in accordance with the Companies Act, 2013 and SEBI Listing Regulations. The company expressed appreciation for Anand’s contributions and disclosed revised committee compositions following his departure, including changes to the Audit Committee, Nomination & Remuneration Committee, Stakeholders Relationship Committee, Corporate Social Responsibility Committee, and Risk Management Committee.

Dr. Agarwal’s Health Care Limited will close its trading window for all designated persons and their immediate relatives starting September 30, 2026, in accordance with its insider trading policy, the company said in a filing to the BSE Limited and National Stock Exchange of India Limited. The closure precedes the finalization and publication of the un-audited financial results for the quarter and half year ending September 30, 2026, and the window will reopen 48 hours after the results are announced by the board of directors.

Dr Agarwals Health Care Ltd share price inched up 0.97% to Rs 483.75 after the company's net profit expanded by 10.13% to Rs 55.02 crore, while revenue from operations slightly gained 8.85% to Rs 614.02 crore in Q2FY26 over Q1FY26. The market capitalization of Hospital industry group stocks on BSE stood at Rs 5.05 lakh crore, easing 4.07%. It has eased by 0.51% over last one week and jumped by 15.67% in last one month while the market capitalization of Dr Agarwals Health Care Ltd has softened by 1.71% and 5.61% in the same period respectively. Profit before tax (PBT) of Dr Agarwals Health Care Ltd stood at Rs 75.14 crore in Q2 FY26, expanding by 40.19% year-on-year, and declining 1.93% quarter-on-quarter. EBITDA came in at Rs 164 crore, rallying 43.27% YoY and climbing 10.15% sequentially. Total expenses saw a slight increase of 8.89% to Rs 521.92 crore in Q2FY26 over Q2FY25. During the quarter, cost of materials consumed stood at Rs 0.32 crore, witnessing a sharp rise of 33.33% YoY, while employee benefits expense was at Rs 121.04 crore, jumping 16.62% YoY. For the TTM ended FY26, revenue from operations witnessed a strong growth of 28.44% to Rs 1711.0 crore, while net profit registered a growth of 16.09% to Rs 110.34 crore, compared to previous TTM. EBITDA jumped by 37733% to Rs 410.36 crore, and PBT improved 13.72% to Rs 159.85 crore compared to previous TTM. The company's consolidated net cash flow from operating activities stood at Rs 360.33 crore in FY26, as against Rs 345.96 crore in FY25. Dr Agarwals Health Care Ltd advanced by 5.53% in last one year, significantly outperforming the benchmark BSE Sensex which has softened by 2.94% during the same period.

Dr Agarwals Health Care will hold a meeting of the Board of Directors of the Company on 4 August 2026.